
Alexandria Real Estate Equities, Inc.

ARE (Alexandria Real Estate Equities, Inc.) trades at 11.3x EV/Revenue — moderately valued for a reits company with strong gross margins (69%) and mature growth profile (-27% YoY). The business is approaching profitability at 12% EBIT margins. Forward PE of 226x.
Companies in the top quartile for ESG metrics have outperformed the bottom quartile by 2.1% annually over the past decade.
Gold Eagle provides data and AI-generated analysis for informational purposes only. Not investment advice. All data from public sources.
Alexandria Real Estate Equities (ARE) is a specialized REIT that owns and develops laboratory and office properties primarily leased to life science and technology companies. They serve as the landlord to pharmaceutical companies, biotechs, research institutions, and government agencies that need specialized facilities for R&D activities. The company generates revenue through long-term lease agreements on properties designed for scientific research and development.
Limited financial data prevents detailed growth analysis, but ARE operates in markets experiencing strong fundamentals driven by pharmaceutical industry expansion and biotech cluster development. The company's growth typically comes from new development projects in key life science hubs and rent escalations on existing properties. Life science real estate has shown resilient demand trends over multiple cycles.
Without recent financial data available, specific margin analysis cannot be provided. However, REITs like ARE typically focus on funds from operations (FFO) and net operating income margins rather than traditional profitability metrics. Specialized life science properties generally command premium rents but require higher upfront capital investment and longer lease-up periods than conventional office space.
ARE is a leading player in the specialized life science real estate niche, competing with other REITs like Boston Properties and BioMed Realty in key biotech clusters. The company's competitive advantage stems from its deep relationships with life science tenants, specialized development expertise, and presence in prime research locations near major universities and hospitals.
No recent earnings data or financial updates are available to assess current momentum. Without quarterly results or management commentary, it's difficult to gauge how the company has been performing relative to expectations or how market conditions have impacted operations.
Limited data availability prevents a comprehensive view of current analyst sentiment or consensus estimates. The life science REIT sector has generally faced headwinds from higher interest rates and biotech funding challenges, but specific analyst views on ARE's positioning would require access to recent research reports.
ARE provides specialized real estate exposure to the life science sector through long-term lease agreements with pharmaceutical and biotech companies, though current financial performance and market positioning cannot be fully assessed due to limited available data.
Pre-generated investor questions answered by Claude Opus. Available in the Atlas AI tab.








| '25E | '26E | '27E | '28E | |
|---|---|---|---|---|
| Revenue | $2.5B | $1.8B | $1.7B | $2.8B |
| Growth | — | (27%) | (4%) | +61% |
| EBITDA | — | $968M | $931M | $1.5B |
| Growth | — | (4%) | +61% | |
| FCF | $1.4B | — | — | — |
| Margin | 58% | — |
What Active REIT Managers Bought And Sold In Q4 2025
7 Ideal 'Safer' Dividend Buys In 38 February ReFa/Ro Dogs
Alexandria Real Estate: A Long-Term Approach Is Required
A Crude Awakening
Alexandria Real Estate Equities, Inc. Named One of the Most Charitable Companies in America by Newsweek
| — |
| — |
| EPS (PF) | $-1.81 | $0.21 | $-0.14 | $-0.21 |
| Growth | — | (167%) |